ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

28,091Medicare Part D Prescriptions Filled, Including Refills

Rank: 20 out of 780

$1.04M Total Retail Price of All Prescriptions

Rank: 63 out of 780

844 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 844 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

37% of this provider’s 844 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

6% of this provider’s 22,212 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
HYDROCODONE-ACETAMINOPHEN 2,069 1,339 S3 1 1
LEVOTHYROXINE SODIUM 1,161 1,022 2 5
OMEPRAZOLE 870 663 3 3
LOVASTATIN 793 668 4 47
FUROSEMIDE 728 620 5 7
AMLODIPINE BESYLATE 661 539 6 4
SIMVASTATIN 595 532 7 2
METOPROLOL TARTRATE 529 435 8 19
GABAPENTIN 497 326 9 13
MELOXICAM 493 370 10 16
METFORMIN HCL 476 375 11 8
PRAVASTATIN SODIUM 473 339 12 9
HYDROCHLOROTHIAZIDE 465 403 13 10
BENAZEPRIL-HYDROCHLOROTHIAZIDE 445 362 10 14 188
ATORVASTATIN CALCIUM 421 377 15 12
NEXIUM 406 311 16 22
CYCLOBENZAPRINE HCL 397 227 R 17 42
CITALOPRAM HBR 391 318 18 23
LISINOPRIL 380 318 19 6
WARFARIN SODIUM 375 336 20 24
BENAZEPRIL HCL 367 331 21 59
ZOLPIDEM TARTRATE 333 245 22 17
SERTRALINE HCL 329 253 23 27
AZITHROMYCIN 326 240 24 38
POTASSIUM CHLORIDE 314 247 25 11
METOPROLOL SUCCINATE 299 281 26 20
ATENOLOL 278 223 27 21
CARVEDILOL 245 224 28 14
LOSARTAN-HYDROCHLOROTHIAZIDE 240 196 29 33
PANTOPRAZOLE SODIUM 235 187 30 25
AMITRIPTYLINE HCL 226 177 R 31 48
FENOFIBRATE 223 168 32 63
TRAMADOL HCL 216 154 33 15
GLYBURIDE-METFORMIN HCL 212 191 R 34 108
LISINOPRIL-HYDROCHLOROTHIAZIDE 206 173 35 26
PROMETHAZINE HCL 201 102 R 36 66
TAMSULOSIN HCL 192 181 37 36
DONEPEZIL HCL 189 182 38 31
LOSARTAN POTASSIUM 188 166 39 18
PAROXETINE HCL 176 119 40 69
TRIAMTERENE-HCTZ 170 156 41 37
METHOCARBAMOL 168 120 R 42 84
FLUTICASONE PROPIONATE 162 124 43 41
ALLOPURINOL 159 143 44 29
CLOPIDOGREL 159 122 44 34
AMOX TR-POTASSIUM CLAVULANATE 153 109 46 135
MECLIZINE HCL 150 103 47 83
CIPROFLOXACIN HCL 146 125 48 49
CRESTOR 141 94 49 32
ALENDRONATE SODIUM 135 134 50 44
CYMBALTA 131 81 51 51
TRAZODONE HCL 126 85 52 35
PREMARIN 126 101 R 52 110
PROAIR HFA 126 83 52 62
FLUOXETINE HCL 123 97 55 65
DILTIAZEM 24HR CD 114 113 56 138
LABETALOL HCL 114 95 56 159
RAMIPRIL 112 102 58 70
PLAVIX 112 86 58 45
DILTIAZEM ER 111 98 60 134
NORTRIPTYLINE HCL 110 83 61 210
DIGOXIN 109 109 62 56
FLUCONAZOLE 106 72 63 111
TRICOR 102 60 64 152
SYNTHROID 102 102 64 77
CLONIDINE HCL 101 65 66 28
ISOSORBIDE MONONITRATE ER 101 76 66 60
GLIMEPIRIDE 96 80 68 30
KLOR-CON M20 95 85 69 57
DIOVAN 92 92 70 55
BISOPROLOL-HYDROCHLOROTHIAZIDE 91 78 71 95
ESCITALOPRAM OXALATE 89 56 72 61
SPIRONOLACTONE 87 75 73 53
MEGESTROL ACETATE 84 76 R 74 161
ADVAIR DISKUS 84 68 74 68
SPIRIVA 84 59 74 72
ESTRADIOL 81 57 R 77 122
NIFEDIPINE ER 81 54 77 115
DOXAZOSIN MESYLATE 80 52 79 97
MIRTAZAPINE 79 65 80 58
ENALAPRIL MALEATE 79 79 80 64
GLYBURIDE 77 72 R 82 101
ACETAMINOPHEN-CODEINE 74 53 S3 83 116
SULFAMETHOXAZOLE-TRIMETHOPRIM 73 41 84 88
CEPHALEXIN 71 49 85 105
NITROFURANTOIN 71 63 85 235
METHYLPREDNISOLONE 69 55 87 92
AMLODIPINE BESYLATE-BENAZEPRIL 69 65 87 50
FOSINOPRIL SODIUM 68 22 89 112
HUMULIN 70-30 67 46 90 106
RANITIDINE HCL 65 45 91 39
DIOVAN HCT 65 62 91 75
GLIPIZIDE ER 65 61 91 109
OXYBUTYNIN CHLORIDE 64 55 94 148
METOCLOPRAMIDE HCL 61 29 95 102
FAMOTIDINE 61 47 95 86
SINGULAIR 60 57 97 73
ACTONEL 60 56 97 264
CARBIDOPA-LEVODOPA 58 52 99 124
AMIODARONE HCL 57 57 100 139
TIZANIDINE HCL 57 47 100 82
VYTORIN 55 38 102 206
PREDNISONE 55 52 102 40
VENLAFAXINE HCL ER 55 41 102 117
NOVOLIN 70-30 54 26 105 164
LYRICA 53 43 106 52
NITROSTAT 53 42 106 244
HYDROXYZINE HCL 52 27 R 108 155
DILTIAZEM 24HR ER 52 52 108 179
RISPERIDONE 51 51 110 98
METOLAZONE 51 48 110 195
DICLOFENAC SODIUM 50 37 112 137
TERAZOSIN HCL 50 50 112 160
ROPINIROLE HCL 50 36 112 87
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.